NCT06075615Withdrawn
A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.
A Multicenter, Observational Study to Describe the Effectiveness and Treatment Patterns of Dacomitinib Among Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Patients With Brain Metastasis
Source: ClinicalTrials.gov · Last updated 7 Feb 2025
Reason given: Sponsor Decision
Brief summary (registry, in English)
The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer which has spread to other parts of the body. This study is seeking participants who: * have lung cancer that has reached at least the brain. * have a type of gene called epidermoid growth factor receptor. A gene is a part of your DNA that has instructions for making things your body needs to work. * have not received any treatment before. All participants in this study will receive dacomitnib 1 time a day. Dacomitinib is a tablet that is taken by mouth at home. They can continue to take dacomitnib until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.
- Status (registry)
- Withdrawn
- Study type
- Observational
- Enrollment
- 0 (actual)
- First submitted
- 18 Sept 2023
- Start date
- 30 Sept 2024
- Primary completion date
- 7 Sept 2026
- Lead sponsor
- Pfizer
- Diseases
- Lung cancer
- NCT number
- NCT06075615
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- any anti-cancer systemic treatment within 12 months prior to index date
- currently on active investigational drug(s) treatment in other clinical studies (Phase 1-4) within 2 weeks before the current study begins and/or during study participation.
Who the study is looking for
- at least 18 years old
- confirmed diagnosis of EGFR mutation-positive NSCLC
- at least one measurable intracranial metastasis
- ECOG-PS of 0, 1 or 2
- dacomitinib as first-line treatment for advanced NSCLC
- Evidence of a personally signed and dated informed consent document (ICD)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.